MCID: INF037
MIFTS: 63

Inflammatory Bowel Disease malady

Categories: Gastrointestinal diseases, Blood diseases, Genetic diseases, Rare diseases, Bone diseases, Immune diseases

Aliases & Classifications for Inflammatory Bowel Disease

Aliases & Descriptions for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 12 3 3 3 3 14
Inflammatory Bowel Diseases 52 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050589
MeSH 42 D015212
NCIt 47 C3138
UMLS 69 C0021390

Summaries for Inflammatory Bowel Disease

Disease Ontology : 12 An intestinal disease characterized by inflammation located in all parts of digestive tract.

MalaCards based summary : Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 2 and collagenous colitis. An important gene associated with Inflammatory Bowel Disease is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Inflammatory bowel disease (IBD) and Innate Immune System. The drugs Infliximab and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and small intestine, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.... more...

Related Diseases for Inflammatory Bowel Disease

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 23
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 12 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 5 Inflammatory Bowel Disease 19
Inflammatory Bowel Disease 3 Inflammatory Bowel Disease 13
Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 16 Inflammatory Bowel Disease 15
Inflammatory Bowel Disease 20 Inflammatory Bowel Disease 28, Early Onset, Autosomal Recessive
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 4
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 22 Inflammatory Bowel Disease 21
Inflammatory Bowel Disease 6 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Early Onset, Autosomal Recessive Il21-Related Infantile Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 568)
id Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 2 34.0 IFNG IL10 IL4 TLR4
2 collagenous colitis 31.6 ABCB1 ATG16L1 CXCL8 IFNG IL10 IL10RA
3 crohn's colitis 31.6 IL17A IL6 MPO NOD2 TLR4 TNF
4 hepatitis 30.8 IFNG IL10 IL6 TNF
5 pyoderma gangrenosum 30.8 CXCL8 IFNG IL1B IL6 TNF
6 tuberculosis 30.5 IL10 IL17A IL1B IL4 IL6 TNF
7 celiac disease 30.5 IL17A NOD2 TNF
8 measles 30.3 IL1B IL6 TNF
9 rosacea 30.3 IFNG IL10 IL1B
10 epidermolysis bullosa 30.1 IFNG IL17A IL4 NOD2 TNF
11 glucocorticoid resistance 30.0 CXCL8 IFNG IL4 MPO
12 neuropathy 30.0 CXCL8 IL1B IL6 TLR4 TNF
13 polyarteritis nodosa 29.9 IFNG IL17A TLR4
14 rheumatoid arthritis 29.9 CXCL8 IFNG IL10 IL17A IL1B IL4
15 gastric dilatation 29.8 CXCL8 IL10 IL17A IL6 TNF
16 histiocytosis 29.7 CXCL8 IL17A IL1B IL6 TLR4 TNF
17 inflammatory bowel disease 1 12.4
18 inflammatory bowel disease 25, early onset, autosomal recessive 12.4
19 inflammatory bowel disease 4 12.4
20 inflammatory bowel disease 5 12.4
21 inflammatory bowel disease 3 12.4
22 inflammatory bowel disease 28, early onset, autosomal recessive 12.4
23 inflammatory bowel disease 20 12.3
24 inflammatory bowel disease 19 12.3
25 inflammatory bowel disease 10 12.3
26 inflammatory bowel disease 13 12.3
27 inflammatory bowel disease 14 12.3
28 inflammatory bowel disease 17, protection against 12.3
29 inflammatory bowel disease 16 12.3
30 inflammatory bowel disease 6 12.3
31 inflammatory bowel disease 7 12.3
32 inflammatory bowel disease 9 12.3
33 inflammatory bowel disease 8 12.3
34 inflammatory bowel disease 12 12.2
35 inflammatory bowel disease 22 12.2
36 inflammatory bowel disease 21 12.2
37 inflammatory bowel disease 15 12.2
38 inflammatory bowel disease 18 12.2
39 inflammatory bowel disease 24 12.2
40 inflammatory bowel disease 23 12.2
41 inflammatory bowel disease 26 12.2
42 inflammatory bowel disease 27 12.2
43 inflammatory bowel disease 11 12.2
44 il21-related infantile inflammatory bowel disease 11.9
45 ulcerative colitis 11.7
46 gastrointestinal defects and immunodeficiency syndrome 11.5
47 crohn's disease 11.4
48 colitis 11.3
49 glycogen storage disease ib 11.3
50 ileitis 11.3

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease

Symptoms & Phenotypes for Inflammatory Bowel Disease

GenomeRNAi Phenotypes related to Inflammatory Bowel Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 MPO NOD1 NOD2 TNF CXCL8 IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 MPO NOD1 NOD2 TNF CXCL8 IL10

MGI Mouse Phenotypes related to Inflammatory Bowel Disease:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 IL23R IL4 IL6 ITPA MPO NOD1
2 homeostasis/metabolism MP:0005376 10.39 ABCB1 ATG16L1 IFNG IL10 IL10RA IL17A
3 immune system MP:0005387 10.36 ABCB1 ATG16L1 IFNG IL10 IL10RA IL17A
4 digestive/alimentary MP:0005381 10.34 IFNG IL10 IL10RA IL17A IL23R IL4
5 growth/size/body region MP:0005378 10.31 ABCB1 ATG16L1 IFNG IL10 IL17A IL23R
6 cardiovascular system MP:0005385 10.24 ITPA MPO TLR4 TNF ABCB1 ATG16L1
7 mortality/aging MP:0010768 10.24 ABCB1 ATG16L1 IFNG IL10 IL17A IL1B
8 endocrine/exocrine gland MP:0005379 10.16 ABCB1 ATG16L1 IFNG IL10 IL17A IL23R
9 liver/biliary system MP:0005370 9.95 ABCB1 IFNG IL10 IL4 IL6 TLR4
10 muscle MP:0005369 9.92 ATG16L1 IFNG IL10 IL6 ITPA MPO
11 reproductive system MP:0005389 9.81 ABCB1 IFNG IL10 IL4 IL6 ITPA
12 neoplasm MP:0002006 9.8 IFNG IL10 IL1B IL23R IL6 TLR4
13 respiratory system MP:0005388 9.56 IFNG IL10 IL17A IL4 IL6 ITPA
14 skeleton MP:0005390 9.28 NOD2 TLR4 TNF IFNG IL10 IL17A

Drugs & Therapeutics for Inflammatory Bowel Disease

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 781)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1 170277-31-3
2
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
3
Clarithromycin Approved Phase 4,Phase 3,Phase 1 81103-11-9 84029
4
Clofazimine Approved, Investigational Phase 4,Phase 3 2030-63-9 2794
5
Rifabutin Approved Phase 4,Phase 3 72559-06-9 6323490
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
9
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-23-7 5754 657311
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
11
Sulfamethazine Approved, Vet_approved Phase 4 57-68-1 5327
12
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
14
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
15
Sucralfate Approved Phase 4 54182-58-0
16
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
17 Parecoxib Approved Phase 4 198470-84-7
18
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
19
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 122320-73-4 77999
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
21
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
22
Azathioprine Approved Phase 4,Phase 2,Phase 3,Phase 1 446-86-6 2265
23
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
24
Ibuprofen Approved Phase 4,Phase 3,Phase 2 15687-27-1 3672
25
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 73590-58-6 4594
26
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 63006 5281004
27
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
28
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 443-48-1 4173
29
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
30
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3 117976-89-3 5029
31
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
32
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
33
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
34
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
35
Ketorolac Approved Phase 4,Phase 2,Phase 1 74103-06-3, 66635-83-4 3826
36
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 53-86-1 3715
37
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 103577-45-3 3883
38
Ticlopidine Approved Phase 4 55142-85-3 5472
39
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
40
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
41
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
42
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
43
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
44
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
45
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 1404-90-6 441141 14969
46
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 65-49-6 4649
47
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
48
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 1 23214-92-8 31703
49
Etoposide Approved Phase 4,Phase 2,Phase 1 33419-42-0 36462
50
Ifosfamide Approved Phase 4,Phase 2 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 2374)
id Name Status NCT ID Phase
1 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4
2 Confocal Endomicroscopy During Endoscopy Unknown status NCT00988273 Phase 4
3 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4
4 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
5 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4
6 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Unknown status NCT02010762 Phase 4
7 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
8 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4
9 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
10 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4
11 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4
12 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4
13 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
14 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4
15 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4
16 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4
17 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
18 Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy Unknown status NCT01698307 Phase 4
19 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
20 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4
21 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4
22 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4
23 Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia Unknown status NCT01789294 Phase 4
24 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4
25 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
26 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
27 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4
28 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
29 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
30 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed NCT02162862 Phase 4
31 Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4
32 Low Volume Colon Preparation for IBD Completed NCT02248337 Phase 4
33 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4
34 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
35 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4
36 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4
37 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4
38 Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy Completed NCT01934088 Phase 4
39 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4
40 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4
41 Post Marketing Surveillance of Remicade Completed NCT00724529 Phase 4
42 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Completed NCT02148718 Phase 4
43 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4
44 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4
45 Pneumococcal Vaccination of Crohn Patients Completed NCT01947010 Phase 4
46 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4
47 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
48 Intragastric and Peritoneal Microdialysis in Infants With Necrotizing Enterocolitis (NEC) Completed NCT00332592 Phase 4
49 Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease Completed NCT01215890 Phase 4
50 Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole Completed NCT00640809 Phase 4

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: inflammatory bowel diseases

Genetic Tests for Inflammatory Bowel Disease

Anatomical Context for Inflammatory Bowel Disease

MalaCards organs/tissues related to Inflammatory Bowel Disease:

39
Colon, T Cells, Small Intestine, Bone, Neutrophil, Endothelial, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Inflammatory Bowel Disease:

18
All Parts Of Digestive Tract

Publications for Inflammatory Bowel Disease

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 2641)
id Title Authors Year
1
Critical role of Keratin 1 in maintaining epithelial barrier and correlation of its down-regulation with the progression of inflammatory bowel disease. ( 28111259 )
2017
2
Successful treatment of Common Variable Immunodeficiency-associated inflammatory bowel disease with Ustekinumab. ( 28333242 )
2017
3
Hypoxia inducible factor-1I+-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease. ( 27921309 )
2017
4
Endoscopic features and genetic background of inflammatory bowel disease complicated with Takayasu arteritis. ( 28449344 )
2017
5
An inflammatory bowel disease-risk variant in INAVA decreases pattern recognition receptor-induced outcomes. ( 28436939 )
2017
6
Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199]. ( 28042931 )
2017
7
Tumor necrosis factor suppresses interleukin 10 in peripheral B cells via upregulating Bcl2-like protein 12 in patients with inflammatory bowel disease. ( 28120341 )
2017
8
Risk of inflammatory bowel disease in patients with rosacea: Results from a nationwide cohort study in Taiwan. ( 28073582 )
2017
9
Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. ( 28089682 )
2017
10
Insight into the role of TSLP in inflammatory bowel diseases. ( 27697608 )
2017
11
Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners. ( 28092305 )
2017
12
Damage of the Mucus Layer: The Possible Shared Critical Common Cause for Both Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). ( 28079624 )
2017
13
Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis. ( 28523573 )
2017
14
Prevalence of inflammatory bowel disease among patients with primary sclerosing cholangitis in Iran. ( 27032493 )
2016
15
Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. ( 27215924 )
2016
16
Association between Toll-Like Receptor 9-1237T/C Polymorphism and the Susceptibility of Inflammatory Bowel Diseases: A Meta-Analysis. ( 26632396 )
2016
17
Pharmacogenetics of drug metabolizing enzyme: thiopurine methyl transferase phenotypes and multidrug resistance 1 gene polymorphism in inflammatory bowel disease. ( 27453281 )
2016
18
Circulating MicroRNA223 is a New Biomarker for Inflammatory Bowel Disease. ( 26844512 )
2016
19
IL23R (Interleukin 23 Receptor) Variants Protective against Inflammatory Bowel Diseases (IBD) Display Loss of Function due to Impaired Protein Stability and Intracellular Trafficking. ( 26887945 )
2016
20
Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. ( 28058009 )
2016
21
AN EPIDEMIOLOGICAL STUDY OF THIOPURINE-METHYLTRANSFERASE VARIANTS IN A CROATIAN INFLAMMATORY BOWEL DISEASE PATIENT COHORT. ( 27333713 )
2016
22
Lymphocyte Antigen 75 Polymorphisms Are Associated with Disease Susceptibility and Phenotype in Japanese Patients with Inflammatory Bowel Disease. ( 27965521 )
2016
23
Editorial - Fiber and the Risk of Flaring in Patients with Inflammatory Bowel Diseases: Lessons From the Crohn's & Colitis Foundation of America Database. ( 27155554 )
2016
24
Colorectal Cancer Risk in Patients With Lynch Syndrome andA Inflammatory Bowel Disease. ( 27521512 )
2016
25
Hypoxia and inflammatory bowel disease. ( 27664046 )
2016
26
Gut and liver T cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. ( 27647428 )
2016
27
Differences in the socio-economic distribution of inflammatory bowel disease and microscopic colitis. ( 27166978 )
2016
28
Overexpression of GRA9 in colonic mucosal cell line partly reflects altered gene expression in colonic mucosa of patients with inflammatory bowel disease. ( 26480216 )
2016
29
Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis. ( 27206015 )
2016
30
Infertility in men with inflammatory bowel disease. ( 27602237 )
2016
31
Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. ( 26831951 )
2016
32
Retrospective evaluation of the clinical utility of serological biomarkers in Chinese patients with inflammatory bowel disease: 2-year clinical experience. ( 27831916 )
2016
33
Ocular Toxoplasmosis Reactivation in a Patient With Inflammatory Bowel Disease Under Treatment With Azathioprine. ( 27031813 )
2016
34
Association between microRNA polymorphisms and the risk of inflammatory bowel disease. ( 27109937 )
2016
35
Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. ( 27189912 )
2016
36
MicroRNA-132 and microRNA-223 control positive feedback circuit by regulating FOXO3a in inflammatory bowel disease. ( 26878986 )
2016
37
Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. ( 27557706 )
2016
38
Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease. ( 26480299 )
2016
39
Association of inflammatory cytokine gene polymorphisms with inflammatory bowel disease in a Moroccan cohort. ( 26632999 )
2016
40
Genetic Risk for Inflammatory Bowel Disease Is a Determinant of Crohn's Disease Development in Chronic Granulomatous Disease. ( 27861181 )
2016
41
Alopecia areata in patients with inflammatory bowel disease: an overview. ( 27513834 )
2016
42
Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported. ( 27193564 )
2016
43
The Polymorphism rs3024505 (C/T) Downstream of the IL10 Gene Is Associated with Crohn's Disease in Serbian Patients with Inflammatory Bowel Disease. ( 27558476 )
2016
44
Autoimmune Pancreatitis and Inflammatory Bowel Disease: An Updated Review. ( 27779612 )
2016
45
Interstitial Nephritis in a Patient with Inflammatory Bowel Disease. ( 27703822 )
2016
46
Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. ( 27002801 )
2016
47
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. ( 27665099 )
2016
48
eQTL analysis links inflammatory bowel disease associated 1q21 locus to ECM1 gene. ( 26738999 )
2016
49
Prevalence of irritable bowel syndrome - like symptoms in Japanese patients with inactive inflammatory bowel disease. ( 27193973 )
2016
50
Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC. ( 27216938 )
2016